The international consensus classification (ICC) now has TP53-mutated AML as a separate entity under “myeloid neoplasms with mutation TP53” to delineate the poor outcomes and highlight the need for better therapies irrespective of blast percent [50]. This evidence concerns the gene TP53 and acute myeloid leukemia.